Thoracic Cancer (Mar 2023)

Old age and EGFR mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan

  • Yuan‐Hung Wu,
  • Yu‐Mei Kang,
  • Yu‐Wen Hu,
  • Keng‐Li Lan,
  • Sang‐Hue Yen,
  • Tzu‐Yu Lai,
  • Tien‐Li Lan,
  • Yuh‐Min Chen,
  • Chao‐Hua Chiu,
  • Yung‐Hung Luo,
  • Heng‐sheng Chao,
  • Chi‐Lu Chiang,
  • Tsu‐Hui Shiao,
  • Chao‐Neng Yang,
  • Wen‐Hu Hsu,
  • Yu‐Chung Wu,
  • Han‐Shui Hsu,
  • Jung‐Jyh Hung,
  • Chien‐Sheng Huang,
  • Po‐Kuei Hsu,
  • Yi‐Wei Chen

DOI
https://doi.org/10.1111/1759-7714.14786
Journal volume & issue
Vol. 14, no. 7
pp. 654 – 661

Abstract

Read online

Abstract Background Stereotactic ablative radiotherapy (SABR) is now the standard of care for patients with inoperable early‐stage lung cancer. Many of these patients are elderly. EGFR (epidermal growth factor receptor) mutation is also common in the Asian population. Methods To evaluate the effects of old age and EGFR mutation on treatment outcomes and toxicity, we reviewed the medical records of 71 consecutive patients with inoperable early‐stage non‐small cell lung cancer (NSCLC) who received SABR at Taipei Veterans General Hospital between 2015 and 2021. Results The study revealed that median age, follow‐up, Charlson comorbidity index, and ECOG score were 80 years, 2.48 years, 3, and 1, respectively. Of these patients, 37 (52.1%) were 80 years or older, and 50 (70.4%) and 21 (29.6%) had T1 and T2 diseases, respectively. EGFR mutation status was available for 33 (46.5%) patients, of whom 16 (51.5%) had a mutation. The overall survival rates at 1, 3, and 5 years were 97.2, 74.9, and 58.3%, respectively. The local control rate at 1, 3, and 5 years was 97.1, 92.5, and 92.5%, respectively. Using Cox proportional hazards regression we found that male sex was a risk factor for overall survival (p = 0.036, 95% CI: 1.118–26.188). Two patients had grade 2 pneumonitis, but no other grade 2 or higher toxicity was observed. We did not find any significant differences in treatment outcomes or toxicity between patients aged 80 or older and those with EGFR mutations in this cohort. Conclusion These findings indicate that age and EGFR mutation status do not significantly affect the effectiveness or toxicity of SABR for patients with inoperable early‐stage NSCLC.

Keywords